RTSS-SMC: Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)

• Sponsor: London School of Hygiene and Tropical Medicine (Other)
• Overall Status: Completed
• CT.gov ID: NCT03143218
• Collaborator: Malaria Research and Training Center, Bamako, Mali (Other), Institut de Recherche en Sciences de la Sante, Burkina Faso (Other)
• Enrollment: 5,920
• Locations: 2
• Arms: 3
• Actual Duration (Months): 35.4
• Patients Per Site: 2960
• Patients Per Site Per Month: 83.5

Study Details

Study Description

Brief Summary

A double-blind, individual randomised trial will be undertaken in 6000 children under the age of five years living in areas of Burkina Faso or Mali where the transmission of malaria is intense and highly seasonal to determine whether the malaria vaccine RTS,S/AS01 is (a) as effective as SMC with SP + AQ in preventing clinical malaria (b) provides additional, useful protection when given together with SMC. The primary trial end-point will be the incidence of clinical episodes of malaria detected by passive case detection.

Condition or Disease	Intervention/Treatment	Phase
Malaria,Falciparum; Children, Only	Biological: RABIPUR®; Biological: RTS,S/AS01; Drug: SMC with SP+AQ; Drug: SMC placebo	Phase 3

Detailed Description

The RTS,S/AS01 malaria vaccine is a recombinant protein vaccine in which the fusion protein RTS (containing parts of the circumsporozoite protein (CSP) of Plasmodium falciparum fused to hepatitis B surface antigen (HBsAg)) is co-expressed in yeast together with free HBsAg (S) to form a virus like particle (RTS,S); it is given with the powerful adjuvant AS01. RTS,S/AS01 induces a strong antibody response to the P. falciparum CSP and high titres of anti-CSP antibody are associated with protection. Following a long process of development, a phase 3 study of RTS,S/AS01 conducted in 15,439 children in 7 countries in Africa showed that three doses of RTS,S/AS01 given with a one month interval between doses, followed by a fourth dose 18 months post dose 3, gave 36.5 % [95% CI 31,41%] protection against clinical attacks of malaria when given to young children aged 5-17 months who were followed for 48 months; efficacy was less when given to infants at the age of 6-12 weeks. RTS,S/AS01 provides a high level of protection during the first three months after vaccination, modelled to be about 70% in the phase 3 trial, a level of initial efficacy similar to that observed in an earlier phase 2 trial in Gambian adults. However, efficacy wanes progressively over the following months. A subsequent dose given 18 months after the primary series restores some but not all of the efficacy seen immediately after the primary series. In July 2015, the European Medicines Agency reviewed efficacy and safety data on RTS.S/AS01 and concluded that the risk benefit balance favoured the vaccine and gave a positive opinion on its use in children aged 6 weeks to 17 months. The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) committee reviewed the vaccine's efficacy and safety in October 2015 and made a number of recommendations on its further evaluation. These included the pilot implementation of RTS,S/AS01 in children aged 5-17 months in 3-5 settings with moderate-to-high malaria transmission intensity, with a preference for areas where SMC is not being delivered, and evaluation of alternative approaches to deployment of the vaccine. Recent evidence from challenge studies conducted in American adult volunteers suggests that a higher level of protection can be obtained when the third dose of the priming schedule is reduced to one fifth of the usual amount and delayed until approximately 6 months post dose 2, and when a reduced dose is used for boosting. In these studies, a vaccine efficacy of 86% was achieved three weeks following priming and 90% efficacy following boosting with a fractional dose. This encouraging result is now being followed in further studies.

SMC involves monthly administration of an antimalarial drug or drug combination in a full therapeutic course to children on three of four occasions during the period of highest risk of malaria infection. Studies undertaken in several countries in West Africa, including Burkina Faso and Mali, have shown that SMC with sulphadoxine/pyrimethamine (SP) and amodiaquine (AQ) is highly effective in areas where the transmission of malaria is markedly seasonal, reducing the incidence of severe and uncomplicated malaria by up to 80%. SMC with a combination of SP and AQ is safe, with no serious drug related adverse event being reported after administration of over 800,000 courses in Senegal. Recent studies have defined the areas where SMC would be an appropriate intervention based on the seasonality and incidence of malaria. These include most of the Sahel and sub-Sahel, population approximately 200 million, and possibly other areas in southern and eastern Africa. A Technical Expert Group of the WHO reviewed all the available evidence on the efficacy and safety of SMC in May 2011 and recommended SMC with SP+AQ in areas of the Sahel and sub-Sahel with highly seasonal transmission. This recommendation was endorsed by the WHO Malaria Policy Advisory Committee (MPAC) in February 2012. Most countries in the Sahel and sub-Sahel region have incorporated SMC, along with other malaria control interventions in their strategic malaria control plan and the implementation of SMC at scale is in progress in many countries in this region through the UNITAID supported SMC ACCESS programme and the support of other major donor organisations. Preliminary evaluation suggests that SMC is providing about 50% protection against clinical malaria when delivered through a national programme (http://www.malariaconsortium.org/pages/access-smc.htm).

SMC is effective but its delivery is demanding on the recipient and provider, requiring four contacts each malaria transmission season if anti-malarials are given to mothers to administer at home and 12 contacts if directly observed treatment is employed. In addition, SMC is threatened by the emergence of resistance to SP and AQ and there are currently no other combinations of licensed antimalarials that could be used to replace them. It is likely to be 5-10 years before novel antimalarials under development could be deployed for SMC. In contrast to SMC, seasonal vaccination with RTS,S/AS01 would require only one visit each transmission season after priming. RTS,S/AS01 may be a little less effective than SMC during the malaria transmission season but this may be balanced by provision of protection during the dry season, when some malaria transmission still occurs and when SMC would provide no benefit. There is, therefore, a need for a comparative study of these two interventions. In some areas where SMC is currently being deployed, and other malaria control interventions such as long-lasting insecticide treated nets used widely, the incidence of malaria in young children remains high (0.4 episodes per year in children under the age of five years in SMC recipients in Burkina Faso). Thus, determining whether RTS,S/AS01 would provide added, useful protection to SMC in such situations is also important. It might also be able to protect some children who, because of side effects, are unable or unwilling to take SMC.

Although the European Medicines Agency has given a positive opinion on RTS,S/AS01, it is not yet certain how this partially effective malaria vaccine can be used most effectively. Three, large-scale pilot implementation studies are being planned by WHO but it is unlikely that, following WHO recommendations, any of these will be conducted in a country where SMC is being delivered. The WHO recommendations on RTS,S/AS01 indicate the need for research on alternative approaches to the delivery of this vaccine. Exploration of the potential of the vaccine to prevent seasonal malaria, taking advantage of its high but rapidly waning efficacy, meets this recommendation and is, therefore, timely.

Study Design

• Study Type: Interventional
• Actual Enrollment: 5920 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: A double-blind, individually randomised trial to compare the incidence of clinical episodes of malaria across three study arms: Seasonal vaccination with the malaria vaccine RTS,S/AS01 Seasonal malaria chemoprevention with SP/AQ Combination of these two interventionsA double-blind, individually randomised trial to compare the incidence of clinical episodes of malaria across three study arms:Seasonal vaccination with the malaria vaccine RTS,S/AS01 Seasonal malaria chemoprevention with SP/AQ Combination of these two interventions
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Prevention
• Official Title: A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined
• Actual Study Start Date: Apr 17, 2017
• Actual Primary Completion Date: Mar 31, 2020
• Actual Study Completion Date: Mar 31, 2020

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: SMC with SP+AQ Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.	Biological: RABIPUR®; Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June); Drug: SMC with SP+AQ; Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
Active Comparator: RTS,S/AS01 Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3.	Biological: RTS,S/AS01; Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June); Drug: SMC placebo; Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
Active Comparator: RTS,S/AS01 PLUS SMC with SP+AQ Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.	Biological: RTS,S/AS01; Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June); Drug: SMC with SP+AQ; Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.

Outcome Measures

Primary Outcome Measures

1. Incidence of Clinical Episodes of Malaria [Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.]

   Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more

Secondary Outcome Measures

1. Clinical Episodes of Uncomplicated Febrile Illness [Passive surveillance in all health centers within the study area, active surveillance in a sub set of study children starting July 2017 till April 2020.]

   Passive and active surveillance to detect cases with temperature > 37.5o C), or a history of fever within the past 48 hours, with a positive blood film (any level of asexual parasitaemia) or a positive rapid diagnostic test (RDT) for malaria

2. Hospital Admissions With Malaria, Including Severe Malaria [Through study completion (30 months), each child admitted in a study hospital will be treated and monitored until complete cure or death (a period of 3 years). Documentation of each hospital admission according to ICH-GCP.]

   Hospital admissions with malaria, including cases of severe malaria which meet WHO criteria for a diagnosis of severe malaria.

3. Prevalence of Malaria Infection Not Severe Enough to Warrant a Clinic Visit [Weekly home visits through study completion from July 2017 - April 2020 to screen study children for malaria.]

   Active surveillance of malaria at household level to assess the prevalence of malaria infection not severe enough to warrant a clinic visit detected in a subset of randomly selected children.

4. Prevalence of Malaria Parasitaemia, Including Gametocytaemia and the Prevalence of Moderate and Severe Anemia and Malnutrition [Blood sample collection during 2-week cross sectional survey at the end of each malaria transmission season.]

   The prevalence of malaria parasitaemia, including gametocytaemia, moderate and severe anaemia and malnutrition at the end of the malaria transmission season

5. Serious Adverse Events (SAEs) [Through study completion (for 30 months), each SAE will be treated and documented according to ICH-GCP.]

   Serious adverse events (SAEs), including any deaths, occurring at any time during the study with special reference to any cases of meningitis and cerebral malaria (WHO case definition)

6. Immune Response to the Vaccine (Anti-CSP Antibody Concentrations) [Blood sample collection prior to 1st dose of vaccine and 1 month after 3rd dose of the primary series of vaccination. In years 2 and 3 blood will be collected before the booster dose and 1 month after administration of the 4th (and 5th) vaccine dose.]

   After priming and after each booster dose, determined in a sub-sample of children

7. Drug Resistance to SP and AQ [Blood sample collection during the 2-week cross sectional survey conducted at the end of malaria transmission season in 2019.]

   The presence of molecular markers of resistance to SP and AQ in parasite positive samples

8. Prevalence of Malaria Parasitaemia in School Aged Children [Blood sample collection during the 2-week cross sectional survey at the end of the malaria transmission season in Year 2 and 3 (November 2018/19).]

   The prevalence of malaria parasitaemia at the end of the malaria transmission season in school-age children resident in the study areas, to determine overall malaria transmission

9. SP+AQ Drug Sensitivity [Children with asymptomatic malaria parasitaemia identified during the final cross-sectional survey (November 2019), treated with a full course of SP+AQ over 3 days and followed for 28 days.]

   The 28-day treatment outcome in children with asymptomatic malaria parasitaemia treated with SP+AQ.

Other Outcome Measures

1. Acceptability of RTS,S and SMC [Data collection in Year 3]

   The acceptability of the two interventions (separately and combined) to the health care deliverers and to the study communities (standardized questionnaires)

2. Feasibility of Introducing Two Malaria Control Strategies Simultaneously [Data collection in Year 3]

   The feasibility of introducing two malaria control strategies simultaneously from the health system perspective (structured observations and interviews with health system officials)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 5 Months to 17 Months
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial

• The child is 5 - 17 months of age at the time of first vaccination

• A parent or legally recognised guardian provides informed consent for the child to join the trial

Exclusion Criteria:

• The child is a transient resident in the study area

• The child is in care

• The age of the child is outside the stipulated range

• The child has a history of an adverse reaction to SP or AQ

• The child has a serious underlying illness, including known HIV infection, unless this is well controlled by treatment, or severe malnutrition (weight for age or mid arm circumference Z scores < 3 SD)

• The child is known to have an immune deficiency disease or is receiving an immunosuppressive drug

• The child has previously received a malaria vaccine.

• The child is enrolled in another malaria intervention trial

• The parents or guardians do not provide informed consent

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest	Ouagadougou		Burkina Faso
2	Malaria Research & Training Center	Bamako		Mali

Sponsors and Collaborators

• London School of Hygiene and Tropical Medicine
• Malaria Research and Training Center, Bamako, Mali
• Institut de Recherche en Sciences de la Sante, Burkina Faso

Investigators

• Study Director: Alassane Dicko, Professor, Malaria Research & Training Center, Bamako
• Study Director: Jean Bosco Ouedraogo, Professor, Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest (IRSS-DRO)

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Apr 2, 2020

More Information

Publications

• Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T; RTS, S Malaria Vaccine Trial Team. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001 Dec 8;358(9297):1927-34.
• Cairns M, Cheung YB, Xu Y, Asante KP, Owusu-Agyei S, Diallo D, Konate AT, Dicko A, Chandramohan D, Greenwood B, Milligan P. Analysis of Preventive Interventions for Malaria: Exploring Partial and Complete Protection and Total and Primary Intervention Effects. Am J Epidemiol. 2015 Jun 15;181(12):1008-17. doi: 10.1093/aje/kwv010. Epub 2015 May 27.
• Cairns M, Roca-Feltrer A, Garske T, Wilson AL, Diallo D, Milligan PJ, Ghani AC, Greenwood BM. Estimating the potential public health impact of seasonal malaria chemoprevention in African children. Nat Commun. 2012 Jun 6;3:881. doi: 10.1038/ncomms1879.
• Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin. 2010 Jan;6(1):90-6. Epub 2010 Jan 30. Review.
• Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, Santara G, Diawara H, Conaré T, Djimde A, Chandramohan D, Cousens S, Milligan PJ, Diallo DA, Doumbo OK, Greenwood B. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011 Feb 1;8(2):e1000407. doi: 10.1371/journal.pmed.1000407.
• Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001 Jan 25;344(4):257-63.
• Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Dama S, Ouologuem D, Dicko A, Doumbo OK. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg. 2008 Mar;78(3):455-61.
• Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, Soulama I, Kangoyé DT, Kaboré Y, Ouédraogo E, Ouédraogo A, Tiono AB, Ouédraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood B, Diallo DA. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011 Feb 1;8(2):e1000408. doi: 10.1371/journal.pmed.1000408.
• NDiaye JL, Cissé B, Ba EH, Gomis JF, Ndour CT, Molez JF, Fall FB, Sokhna C, Faye B, Kouevijdin E, Niane FK, Cairns M, Trape JF, Rogier C, Gaye O, Greenwood BM, Milligan PJ. Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial. PLoS One. 2016 Oct 20;11(10):e0162563. doi: 10.1371/journal.pone.0162563. eCollection 2016. Erratum in: PLoS One. 2016 Dec 8;11(12 ):e0168421.
• Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M, Abdulla S, Adjei S, Agbenyega T, Agnandji ST, Aide P, Anderson S, Ansong D, Aponte JJ, Asante KP, Bejon P, Birkett AJ, Bruls M, Connolly KM, D'Alessandro U, Dobaño C, Gesase S, Greenwood B, Grimsby J, Tinto H, Hamel MJ, Hoffman I, Kamthunzi P, Kariuki S, Kremsner PG, Leach A, Lell B, Lennon NJ, Lusingu J, Marsh K, Martinson F, Molel JT, Moss EL, Njuguna P, Ockenhouse CF, Ogutu BR, Otieno W, Otieno L, Otieno K, Owusu-Agyei S, Park DJ, Pellé K, Robbins D, Russ C, Ryan EM, Sacarlal J, Sogoloff B, Sorgho H, Tanner M, Theander T, Valea I, Volkman SK, Yu Q, Lapierre D, Birren BW, Gilbert PB, Wirth DF. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. N Engl J Med. 2015 Nov 19;373(21):2025-2037. doi: 10.1056/NEJMoa1505819. Epub 2015 Oct 21.
• Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, White MT, Wenger EA, Van de Velde N, Pemberton-Ross P, Griffin JT, Smith TA, Eckhoff PA, Muhib F, Jit M, Ghani AC. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016 Jan 23;387(10016):367-375. doi: 10.1016/S0140-6736(15)00725-4. Epub 2015 Nov 6.
• Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995 Jun;52(6):565-8.
• Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK, Hauns KD, Komisar JL, Qabar AN, Davidson SA, Dutta S, Griffith ME, Magee CD, Wojnarski M, Livezey JR, Kress AT, Waterman PE, Jongert E, Wille-Reece U, Volkmuth W, Emerling D, Robinson WH, Lievens M, Morelle D, Lee CK, Yassin-Rajkumar B, Weltzin R, Cohen J, Paris RM, Waters NC, Birkett AJ, Kaslow DC, Ballou WR, Ockenhouse CF, Vekemans J. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study. J Infect Dis. 2016 Sep 1;214(5):762-71. doi: 10.1093/infdis/jiw237. Epub 2016 Jun 13.
• RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015 Jul 4;386(9988):31-45. doi: 10.1016/S0140-6736(15)60721-8. Epub 2015 Apr 23. Erratum in: Lancet. 2015 Jul 4;386(9988):30.
• Swysen C, Vekemans J, Bruls M, Oyakhirome S, Drakeley C, Kremsner P, Greenwood B, Ofori-Anyinam O, Okech B, Villafana T, Carter T, Savarese B, Duse A, Reijman A, Ingram C, Frean J, Ogutu B; Clinical Trials Partnership Committee. Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J. 2011 Aug 4;10:223. doi: 10.1186/1475-2875-10-223.
• White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, Adjei S, Agbenyega T, Ogutu B, Otieno L, Otieno W, Agnandji ST, Lell B, Kremsner P, Hoffman I, Martinson F, Kamthunzu P, Tinto H, Valea I, Sorgho H, Oneko M, Otieno K, Hamel MJ, Salim N, Mtoro A, Abdulla S, Aide P, Sacarlal J, Aponte JJ, Njuguna P, Marsh K, Bejon P, Riley EM, Ghani AC. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015 Dec;15(12):1450-8. doi: 10.1016/S1473-3099(15)00239-X. Epub 2015 Sep 2.
• Wilson AL; IPTc Taskforce. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One. 2011 Feb 14;6(2):e16976. doi: 10.1371/journal.pone.0016976. Review.
• Xu Y, Cheung YB, Lam KF, Milligan P. Estimation of summary protective efficacy using a frailty mixture model for recurrent event time data. Stat Med. 2012 Dec 20;31(29):4023-39. doi: 10.1002/sim.5458. Epub 2012 Jul 5.

• Responsible Party: Brian Greenwood, Professor, London School of Hygiene and Tropical Medicine
• ClinicalTrials.gov Identifier: NCT03143218
• Other Study ID Numbers: ITDCZJ29 - Greenwood
• First Posted: May 8, 2017
• Last Update Posted: Apr 7, 2022
• Last Verified: Mar 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Brian Greenwood, Professor, London School of Hygiene and Tropical Medicine: Malaria; Seasonal vaccination; Seasonal chemoprevention
• Additional relevant MeSH terms: Malaria; Malaria, Falciparum

Study Results

Participant Flow

Arm/Group Title	SMC With SP+AQ	RTS,S/AS01	RTS,S/AS01 PLUS SMC With SP+AQ
Arm/Group Description	Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3. RABIPUR®: Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June) SMC with SP+AQ: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.	Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3. RTS,S/AS01: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June) SMC placebo: Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season	Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3. RTS,S/AS01: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June) SMC with SP+AQ: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
Period Title: Overall Study
STARTED	1965	1988	1967
COMPLETED	1716	1734	1740
NOT COMPLETED	249	254	227

Baseline Characteristics

Arm/Group Title	SMC With SP+AQ	RTS,S/AS01	RTS,S/AS01 PLUS SMC With SP+AQ	Total
Arm/Group Description	Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3. RABIPUR®: Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June) SMC with SP+AQ: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.	Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3. RTS,S/AS01: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June) SMC placebo: Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season	Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3. RTS,S/AS01: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June) SMC with SP+AQ: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.	Total of all reporting groups
Overall Participants	1965	1988	1967	5920
Age, Customized (Count of Participants)
Under 8 months	471 24%	448 22.5%	463 23.5%	1382 23.3%
8-11 months	532 27.1%	527 26.5%	531 27%	1590 26.9%
12-15 months	486 24.7%	552 27.8%	537 27.3%	1575 26.6%
16 months or older	476 24.2%	461 23.2%	436 22.2%	1373 23.2%
Sex: Female, Male (Count of Participants)
Female	950 48.3%	956 48.1%	948 48.2%	2854 48.2%
Male	1015 51.7%	1032 51.9%	1019 51.8%	3066 51.8%
Race and Ethnicity Not Collected (Count of Participants)
Count of Participants [Participants]	0 0%
Region of Enrollment (participants) [Number]
Burkina Faso	936 47.6%	911 45.8%	930 47.3%	2777 46.9%
Mali	1029 52.4%	1077 54.2%	1037 52.7%	3143 53.1%
LLIN use the night before the 2017 census (Count of Participants)
Yes	1593 81.1%	1580 79.5%	1577 80.2%	4750 80.2%
No	360 18.3%	391 19.7%	380 19.3%	1131 19.1%
Missing	12 0.6%	17 0.9%	10 0.5%	39 0.7%
PCV vaccination (Count of Participants)
Yes	1650 84%	1646 82.8%	1642 83.5%	4938 83.4%
No	82 4.2%	99 5%	74 3.8%	255 4.3%
Card not available	172 8.8%	175 8.8%	171 8.7%	518 8.8%
Card available but incomplete	61 3.1%	67 3.4%	79 4%	207 3.5%
Missing	0 0%	1 0.1%	1 0.1%	2 0%
Penta vaccination (Count of Participants)
Yes	1650 84%	1647 82.8%	1650 83.9%	4947 83.6%
No	87 4.4%	95 4.8%	78 4%	260 4.4%
Card not available	169 8.6%	179 9%	167 8.5%	515 8.7%
Card available but incomplete	58 3%	66 3.3%	67 3.4%	191 3.2%
Missing	1 0.1%	1 0.1%	5 0.3%	7 0.1%
MenAfriVac vaccination (Count of Participants)
Yes	468 23.8%	477 24%	478 24.3%	1423 24%
No	1245 63.4%	1251 62.9%	1251 63.6%	3747 63.3%
Missing	252 12.8%	260 13.1%	238 12.1%	750 12.7%

Outcome Measures

1. Primary Outcome

Title	Incidence of Clinical Episodes of Malaria
Description	Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more
Time Frame	Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	SMC With SP+AQ	RTS,S/AS01	RTS,S/AS01 PLUS SMC With SP+AQ
Arm/Group Description	Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3. RABIPUR®: Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June) SMC with SP+AQ: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.	Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3. RTS,S/AS01: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June) SMC placebo: Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season	Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3. RTS,S/AS01: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June) SMC with SP+AQ: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
Measure Participants	1965	1988	1967
Number (95% Confidence Interval) [No. of events/1000 person years at risk]	304.8	278.2	113.3

2. Secondary Outcome

Title	Clinical Episodes of Uncomplicated Febrile Illness
Description	Passive and active surveillance to detect cases with temperature > 37.5o C), or a history of fever within the past 48 hours, with a positive blood film (any level of asexual parasitaemia) or a positive rapid diagnostic test (RDT) for malaria
Time Frame	Passive surveillance in all health centers within the study area, active surveillance in a sub set of study children starting July 2017 till April 2020.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

3. Secondary Outcome

Title	Hospital Admissions With Malaria, Including Severe Malaria
Description	Hospital admissions with malaria, including cases of severe malaria which meet WHO criteria for a diagnosis of severe malaria.
Time Frame	Through study completion (30 months), each child admitted in a study hospital will be treated and monitored until complete cure or death (a period of 3 years). Documentation of each hospital admission according to ICH-GCP.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

4. Secondary Outcome

Title	Prevalence of Malaria Infection Not Severe Enough to Warrant a Clinic Visit
Description	Active surveillance of malaria at household level to assess the prevalence of malaria infection not severe enough to warrant a clinic visit detected in a subset of randomly selected children.
Time Frame	Weekly home visits through study completion from July 2017 - April 2020 to screen study children for malaria.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

5. Secondary Outcome

Title	Prevalence of Malaria Parasitaemia, Including Gametocytaemia and the Prevalence of Moderate and Severe Anemia and Malnutrition
Description	The prevalence of malaria parasitaemia, including gametocytaemia, moderate and severe anaemia and malnutrition at the end of the malaria transmission season
Time Frame	Blood sample collection during 2-week cross sectional survey at the end of each malaria transmission season.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

6. Secondary Outcome

Title	Serious Adverse Events (SAEs)
Description	Serious adverse events (SAEs), including any deaths, occurring at any time during the study with special reference to any cases of meningitis and cerebral malaria (WHO case definition)
Time Frame	Through study completion (for 30 months), each SAE will be treated and documented according to ICH-GCP.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

7. Secondary Outcome

Title	Immune Response to the Vaccine (Anti-CSP Antibody Concentrations)
Description	After priming and after each booster dose, determined in a sub-sample of children
Time Frame	Blood sample collection prior to 1st dose of vaccine and 1 month after 3rd dose of the primary series of vaccination. In years 2 and 3 blood will be collected before the booster dose and 1 month after administration of the 4th (and 5th) vaccine dose.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

8. Secondary Outcome

Title	Drug Resistance to SP and AQ
Description	The presence of molecular markers of resistance to SP and AQ in parasite positive samples
Time Frame	Blood sample collection during the 2-week cross sectional survey conducted at the end of malaria transmission season in 2019.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

9. Secondary Outcome

Title	Prevalence of Malaria Parasitaemia in School Aged Children
Description	The prevalence of malaria parasitaemia at the end of the malaria transmission season in school-age children resident in the study areas, to determine overall malaria transmission
Time Frame	Blood sample collection during the 2-week cross sectional survey at the end of the malaria transmission season in Year 2 and 3 (November 2018/19).

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

10. Secondary Outcome

Title	SP+AQ Drug Sensitivity
Description	The 28-day treatment outcome in children with asymptomatic malaria parasitaemia treated with SP+AQ.
Time Frame	Children with asymptomatic malaria parasitaemia identified during the final cross-sectional survey (November 2019), treated with a full course of SP+AQ over 3 days and followed for 28 days.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

11. Other Pre-specified Outcome

Title	Acceptability of RTS,S and SMC
Description	The acceptability of the two interventions (separately and combined) to the health care deliverers and to the study communities (standardized questionnaires)
Time Frame	Data collection in Year 3

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

12. Other Pre-specified Outcome

Title	Feasibility of Introducing Two Malaria Control Strategies Simultaneously
Description	The feasibility of introducing two malaria control strategies simultaneously from the health system perspective (structured observations and interviews with health system officials)
Time Frame	Data collection in Year 3

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

Adverse Events

Time Frame	Serious adverse event data were collected over a 3 year period, from 1st April 2017 to 31st March 2020.
Adverse Event Reporting Description	The number of participants at risk for other (non-serious) adverse events is zero because non-serious adverse events were not collected or assessed as part of this study.
Arm/Group Title	SMC With SP+AQ		RTS,S/AS01		RTS,S/AS01 PLUS SMC With SP+AQ
Arm/Group Description	Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3. RABIPUR®: Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June) SMC with SP+AQ: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.		Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3. RTS,S/AS01: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June) SMC placebo: Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season		Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3. RTS,S/AS01: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June) SMC with SP+AQ: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
All Cause Mortality
	SMC With SP+AQ		RTS,S/AS01		RTS,S/AS01 PLUS SMC With SP+AQ
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	32/1965 (1.6%)		27/1988 (1.4%)		15/1967 (0.8%)
Serious Adverse Events
	SMC With SP+AQ		RTS,S/AS01		RTS,S/AS01 PLUS SMC With SP+AQ
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	97/1965 (4.9%)		94/1988 (4.7%)		71/1967 (3.6%)
General disorders
Non-fatal SAEs	65/1965 (3.3%)		67/1988 (3.4%)		56/1967 (2.8%)
Fatal SAEs	32/1965 (1.6%)		27/1988 (1.4%)		15/1967 (0.8%)
Other (Not Including Serious) Adverse Events
	SMC With SP+AQ		RTS,S/AS01		RTS,S/AS01 PLUS SMC With SP+AQ
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/0 (NaN)		0/0 (NaN)		0/0 (NaN)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.